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Abstract: CD3 antigen is a crucial molecule in T cell signal transduction. Although its expression on cell surface is constitutive,
dynamic regulation of TCR-CD3 level is probably the most important mechanism allowing T cells to calibrate their response
to different levels of stimuli. In our study we examined the role of two main T cell signal transduction pathways in controlling
the surface level of CD3 antigen, one based on protein kinase C activity and the other dependent on calcineurin. As an
experimental model we used three clones derived from Jurkat cell line, expressing different levels of CD3 antigen surface
expression: CD3low (217.6), CD3+(217.9) or CD3low/+ (217.7). The cells were stimulated with PMA or ionomycin, acting directly
on PKC and calcineurin, respectively. Prior to the stimulation cells were incubated with PKC inhibitor - chelerythrine or
calcineurin blocker - cyclosporine A. Changes in CD3 surface expression were measured by flow cytometry. Only PMA and
chelerythrine were able to change CD3 expression suggesting important involvement of PKC in the regulation of its expression.
To confirm these findings, PKC activity was estimated in Jurkat clones. Our data demonstrated that Jurkat clones with different
CD3 expression showed also different PKC activities, so we conclude that PKC-dependent pathway is the main way of
controlling CD3 level on Jurkat clones.
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Introduction
CD3 antigen is a multimeric protein, consisting of two
heterodimers: CD3εγ, CD3εδ and one homodimer
CD3ζζ, expressed exclusively on the surface of T cells,
in combination with TCR chains [10]. Sophisticated and
selective mechanisms allow only the expression of com-
pletely assembled and functional receptors [7]. A con-
stitutive, but at the same time dynamic CD3 expression
plays physiologically important role in the regulation of
T cell function [8]. One of the mechanisms responsible
for CD3 down-modulation, occurring physiologically
after T cell stimulation, is dependent on the protein
kinase C activity. PKC phosphorylates a serine residue
after recognising a leucine based motif in the CD3γ
chain, causing internalisation of the whole CD3-TCR
complex [2]. As T cell activation is known to correlate
with the degree of TCR down-modulation [8], this pro-
cess appears to play an important role in the regulation
of T cell function. Heterogeneity of CD3 surface level
is a common feature of many pathologies including T
cell lymphoma [11] and still not much is known about
the principles of such aberrations as well as about the
exact mechanism governing the expression of the inves-
tigated antigen. Therefore we addressed the question
about the importance of two main T cell signalling
pathways, one based on PKC and the other on calci-
neurin activity, in controlling CD3 surface level.
Materials and methods
Jurkat human T cell line (E 6.1) heterogeneous in respect to CD3
surface expression was subcloned, using limited dilutions method,
into 3 clones stably expressing different levels of CD3. Clone 217.6
expressed low levels of CD3 (CD3low), clone 217 .9 showed high
CD3 surface expression (CD3+) and on clone 217.7 CD3 expression
was bimodal, low and high (CD3low/+). Cells were cultured in RPMI
1640 (Sigma, USA) with 10% FCS, penicillin, streptomycin and 2
mM glutamine (complete medium) at 37˚C in 5% CO2.  
Cells were suspended  at concentration of 1×106 cells/ml in
complete medium and incubated at 37˚C in 5% CO2 for 6 h with
and without PKC stimulator - PMA and calcineurin stimulator - iono-
mycin at a concentration of 0.05 µg/ml and 0.5 µM, respectively. Prior
to stimulation, the cells were incubated for 1 h in the same
conditions with PKC inhibitor - chelerythrine (0.1 µg/ml) or
calcineurin inhibitor - cyclosporine A (1 µM). CD3 surface expression
was measured by staining with anti-CD3ε monoclonal antibody con-
jugated with FITC (DAKO, Denmark). Cytometric analysis was
performed on the FACSCalibur (Becton Dickinson) at the De-
partment of Clinical Biochemistry, or Galaxy (DAKO) or FAC-
Scan (Becton Dickinson) at the Department of Pathophysiology,
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Medical University of Gdan´sk. Data were analysed with WinM-
DI, version 2.9 (J. Trotter, The Scripps Research Institute). 
PKC activity was examined with the use of PepTag® Assay for
Non-Radioactive Detection of Protein Kinase C (Promega, USA).
Cells were initially treated with chelerythrine and later incubated
with/without PMA for 15 min; a portion of cells was left unstimulated
as a control of spontaneous PKC expression. Cells were lysed after
being adjusted to 5×106 in 0.5 ml, in the extraction buffer (25 mM
Tris-HCL (pH 7.4), 0.5 EDTA, 0.5 EGTA, 0.05% Triton®1 X-100,
10 mM mercaptoethanol, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 0.2
mM sodium vanadate, 1% PMSF in 100% ethanol) and then soni-
cated for 30 sec using Sonoplus 2070 (Bandelin Electronic, Ger-
many). Cell extracts were centrifugated at 10000 × g for 20 min, and
the membrane and cytoplasmic fraction was collected. The amount
of proteins in lysates was measured by Bradford method. One µg of
protein was used for further analysis. During PKC assay, PKC
activator - phosphatidyl serine (PS), provided by the producer was
used alternatively for the enzyme stimulation. Probes prepared in
order to estimate PKC activity included 5 µl reaction buffer, 5 µl C1
peptide, 1 µl peptide protection solution, 9 µl PKC probe, and 5 µl
activator solution (optional). Probes without and with 10 µg of pure
PKC were used as negative and positive controls, respectively. Final
reaction mixture of all probes was 25 µl. Cell extracts containing
PKC were added just before incubation which was performed for 30
min at 30˚C. Reaction was stopped by boiling in water bath for 10
min. Probes with 1 µl of 80% glycerol were loaded onto 0.8% agarose
gel and separated at 100 V for 40 min. Fluorescent bands of different
electrophoretic mobility were visualized by UV transillumination
and the pictures were stored for densitometric analysis using GDS-
8000 Gel Documentation System and Labworks 4.0 (UVP, UK).
Results
Three Jurkat clones with different CD3 expression were
used as an experimental model, allowing to investigate
modulation of CD3 surface expression depending on
two signalling pathways in T cells. PMA stimulation
decreased CD3 expression on all Jurkat clones (Fig.
Fig. 1. Diversified effect of chelerythrine on CD3 expession depends on the initial receptor level. Jurkat clones express different levels of
CD3 antigen: low on 217.6 clone (A), high on 217.9 (B) and ranging from low to high levels on clone 217.7 (C). PMA down-modulated
CD3 expression on all clones (D, E, F), but effect of chelerythrine with PMA on CD3 expression was different for clones 217.6 (D) and
217.9 (E). Chelerythrine alone increased CD3 expression on clone 217.6 (G), and on low CD3 expressors of clone 217.7 CD3+ (I). Fig. 2.
Varied protein kinase C activity in three Jurkat clones. PKC activity in the Jurkat clones is much higher than in PBMC. The lowest activity
was observed in 217.6 clone and high in 217.9 and 217.7 clones. Phosphatidyl serine (PS) increased PKC activity in all investigated cells.
PMA decreased PKC activity in 3 clones, while increasing its activity in PBMC. Chelerythrine acted as PKC stimulator for all cells. PBMC
treated with the combination of PMA and chelerythrine showed increased PKC activity, in contrast to Jurkat clones. 
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1D-F). Neither ionomycin nor calcineurin inhibitor cy-
closporine A exerted any effect on CD3 expression on
Jurkat cells (data not shown). Chelerythrine exhibited
diverse effect on the CD3 antigen expression, dependent
on its initial level. It increased CD3 surface expression
on 217.6 clone when used alone, as well as in combina-
tion with PMA, inverting the effect of the stimulator
(Fig. 1G). On 217.9 clone (CD3+), chelerythrine not only
did not invert PMA effect, but even increased CD3
down-modulating caused by PMA (Fig. 1E). Effects on
the 217.7 clone, exhibiting CD3 expression ranging
from low to high, confirmed previous observations as
chelerythrine increased the CD3 level in the population
with low level of the receptor and enhanced the PMA
down-modulating effect on the population with high
antigen level (Fig. 1F, I) . These results suggested a very
important role of PKC in the regulation of CD3 express-
ion. 
To confirm that role, PKC activity was measured.
The initial enzyme activity in all Jurkat clones was much
higher than in normal PBMC (Fig. 2). Different PKC
activity was determined in the investigated Jurkat
clones. Clone 217.6 exhibited the lowest PKC activity,
while clones 217.9 and 217.7 showed similar enzyme
activity. Phosphatydyl serine increased PKC activity in
all three Jurkat clones as well as in PBMC. Surprisingly,
PMA appeared to inhibit PKC activity in Jurkat clones,
but still was acting as an activator in PBMC. Paradoxi-
cally, chelerythrine increased PKC activity in all inves-
tigated cell types. In combination with PMA it decreased
PKC expression on clone 217.6 to a much greater extent
than on two other Jurkat clones (Fig. 2).
Discussion
Our experimental model based on three Jurkat clones
with different CD3 expression, allowed us to examine
whether signalling pathway dependent on protein kinase
C and the one dependent on calcineurin, have any in-
fluence on CD3 expression regulation, in relation to its
initial level of expression. Results obtained from stimu-
lation and inhibition experiments measuring CD3 ex-
pression by flow cytometry suggested that calcineurin
does not play a significant role in CD3 modulation, while
PKC is a crucial enzyme in this process. PKC has been
previously reported to participate in the proliferation and
survival of cancer cells [6]. We showed that in all Jurkat
clones PKC activity was much higher than in PBMC
from healthy donors. Additionally, Jurkat cells reacted
differently than normal lymphocytes to PMA treatment,
by lowering PKC activity. This difference can be ex-
plained by the fact that part of PKC pool in Jurkat clones
is initially activated, so PMA initiated its degradation
since it is known to exert such effect on active kinase
form [3]. Chelerythrine considered in some reports as a
specific PKC inhibitor [5], appeared to act as a stimula-
tor used at the concentration of 0.1 µg/ml, as suggested
previously [9]. Additionally, it exerted diverse effect on
CD3 expression in the clones depending on the initial
level of receptors. Jurkat cells are known to express all
isoforms of PKC [1], but as leukemic cells they can have
some specific isoforms in bigger proportion [4] which
can be the reason of CD3 initial level-dependent antigen
regulation mechanism.
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